Tom Powles

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2024
September 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  

Tom Powles
Sep 19, 2024, 15:48 | Insight
Tom Powles: The 1st perioperative immune therapy study to show an OS in bladder cancer
Tom Powles shared a post on X: “Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder…
Sep 19, 2024, 04:32 | Societies
Best of ESMO24
The ESMO Congress 2024 took place in Barcelona, from September 13 to 17, 2024, at…
Sep 17, 2024, 16:42 | Blog
Tom Powles: SUNNIFORCAST at ESMO24
Tom Powles shared a post on X: "SUNNIFORCAST at ESMO24 ipi/nivo vs VEGF based therapy…
Sep 17, 2024, 10:06 | Insight
Sumanta K. Pal: Important analysis of SWOG 1500 published just ahead of ESMO24
Sumanta K. Pal shared a post on X: "Huge congrats to Pedro C Barata, who drove…
Sep 16, 2024, 16:31 | Societies
40 Posts Not To Miss From ESMO24 Day 3
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the…
Sep 16, 2024, 16:18 | Societies
Key Findings from the NIAGARA Trial at ESMO 2024
The results of the NIAGARA trial were recently presented at ESMO 2024. The NIAGARA trial,…
Sep 15, 2024, 12:53 | Blog
Sumanta Pal's highlights from ESMO24
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the…
Sep 14, 2024, 17:15 | Societies
45 Posts not to miss from ESMO24 Day 1
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at…
Sep 14, 2024, 15:38 | Insight
ESMO24 Day 1 highlights by Tom Powles
The ESMO Congress 2024 (ESMO24) is taking place from 13-17 September 2024, in Barcelona. ESMO24…
Sep 10, 2024, 14:54 | Blog
Tom Powles: Belzutifan for clear cell renal cancer
Tom Powles shared a post on X: “Belzutifan significantly outperformed Everolimus in heavily pretreated clear…
Sep 10, 2024, 05:00 | Blog
Tian Zhang: Lots of bladder cancer data coming at ESMO24
Tian Zhang shared a post on X by Tom Powles adding: "Lots of bladder cancer…
Sep 9, 2024, 14:16 | Blog
Tom Powles: Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions
Tom Powles shared a post on X, about recent paper published in ESMO Open: The…
Aug 27, 2024, 19:10 | Blog
Petros Grivas: Looking forward to a fantastic ESMO24
Petros Grivas shared a post on X by ESMO, adding: "Looking forward to a fantastic…
Aug 26, 2024, 21:30 | Blog
Tian Zhang: 3 weeks til ESMO24!
Tian Zhang shared a post by ESMO on X, adding the following: “T -3 weeks…
Aug 26, 2024, 20:08 | Insight
Tom Powles: Belzutifan significantly outperformed Everolimus in heavily pretreated clear cell renal cancer
Tom Powles, Professor of urology cancer at the University of London and the Director of…
Aug 14, 2024, 12:07 | Blog
Oncoinfluencers to Follow on Social Media: Dr. Tom Powles
We are excited to spotlight Dr. Tom Powles, a leading expert in urological oncology, as…
Aug 6, 2024, 03:43 | Blog
Tian Zhang: CtDNA to replace radiology for disease recurrence?
Tian Zhang posted on X: "Fiery discussion on minimal residual disease for bladder cancer —…
Aug 4, 2024, 17:13 | Insight
Shilpa Gupta: Community oncologists discuss the real world practice patterns in GU cancers at WorldGU24
Shilpa Gupta shared on X: “WorldGU24, An amazing session with The Uromigos, Tom Powles, Brian Rini…
Aug 4, 2024, 14:30 | Societies
8 Posts Not To Miss From GUWorld24!
The 2024 World Conference On Genitourinary Cancers (GUWorld24) took place from August 1st to 3rd…
Jul 30, 2024, 12:56 | Blog
Tian Zhang: Uromigos anticipating some lively discussions
Tian Zhang shared a post by Uromigos on X, adding: "See you next week at World GU,…
Jul 28, 2024, 13:01 | Insight
Brian Rini: Excited for our session with WorldGU24
Brian Rini, Chief of Clinical Trials at Vanderbilt University, shared a post by Uromigos on…
Jul 28, 2024, 08:32 | Blog
At ANZUP 24 Cristiane Bergerot presented a new HRQOL measure for patients with localized and metastatic RCC - Florez Lab
Florez Lab shared on X: "At ANZUP 24 Dr. Cristiane Bergerot presented a new HRQOL…
Jul 21, 2024, 09:13 | Insight
Sumanta K. Pal: Excellent review on kidney cancer from Tom Powles
Sumanta K. Pal shared on X a recent paper by Matthew Young et al. titled…
Jul 20, 2024, 18:07 | Blog
Tom Powles: More evidence that PD(L)1 re-challenge should be avoided in renal cancer
Tom Powles posted on X/Twitter: "More evidence that PD(L)1 re-challenge should be avoided in renal…
Jul 14, 2024, 21:15 | Blog
Sumanta K. Pal: Excellent use of Twitter polls to reconcile tough clinical scenarios
Sumanta K. Pal shared a post on X: ''Brilliant insights from Tom Powles, Barts Cancer Institute.…
Jul 14, 2024, 05:39 | Blog
Thomas Powles: An intratumoral micro-device releases small amounts of drugs locally to assess efficacy
Thomas Powles posted on X: "An intratumoral micro-device releases small amounts of drugs locally to…
Jul 13, 2024, 12:22 | Insight
Key Highlights from KCRS24 by Sumanta K. Pal
Kidney Cancer Research Summit or the KCRS24 was a conference held on 11th-12th July in Boston focused…
Jul 12, 2024, 13:32 | Societies
Insights from KCRS24 by Neeraj Agarwal
Kidney Cancer Research Summit or the KCRS24 was a conference held on 11th-12th July in…
Jul 10, 2024, 11:57 | Blog
The 2024 Uromigos Cup
Uromigos formed in early 2017 as a group of friends attempting to provide balanced, scientific content…
Jul 7, 2024, 14:06 | Blog
Christian Gratzke: Great to have Tom Powles at Uro Trials
Christian Gratzke, Urologic Surgeon and Chair at University of Freiburg, shared on X: "Great to have…
Jul 7, 2024, 04:49 | Insight
Harold J. Burstein: Important questions about 'getting to 2nd line therapy.'
Harold J. Burstein, Breast cancer specialist and professor at Dana Farber Cancer Institute, shared a…
Jul 6, 2024, 13:29 | Blog
ESMO - immune cell-related biomarkers in metastatic HNSCC
ESMO shared on LinkedIn: "Latest podcast. Annals of Oncology Editor in Chief Tom Powles talks to…
Jul 6, 2024, 08:45 | Insight
Tom Powles on RCC patients receiving ICI therapy
Tom Powles shared on X: “During the period of PD-1 inhibition availability for RCC in…
Jul 5, 2024, 05:41 | Blog
Abeid Athman: Joining ASCO had a huge role in shaping my career
Abeid Athman, Clinical Oncologist at Kenyatta University Hospital, shared on X: "It has been 5…
Jul 2, 2024, 11:12 | Blog
Enrique Grande: Fabulous and inspiring view of the short term future of advanced bladder cancer
Enrique Grande shared a post on X:                 …
Jul 1, 2024, 14:48 | Blog
Daniel Castellano: Great proposals in a urothelial cancer workshop at GUARD Symposium 2024
Daniel Castellano, Medical Oncologist at University Hospital October 12, shared on X: “Great discussion and…
Jul 1, 2024, 01:24 | Blog
Daniel Castellano: Biomarker selected bladder sparing preservation program is the future
Daniel Castellano, Medical Oncologist at University Hospital October 12, shared on X: "Excellent and clarifier…
Jun 26, 2024, 13:51 | Insight
Tom Powles: Durvalumab with neoadjuvant chemo then cystectomy in MIBC
Tom Powles shared on X: "Positive results from the NIAGARA Phase III trial showed durvalumab…
Jun 26, 2024, 03:43 | Blog
Roberto Iacovelli: Honour to have TIDE-A commented by Laurence Albiges, Tom Powles and Dr. Wells
Roberto Iacovelli shared a post on X: "Great honor to have TIDE-A commented by Laurence…
Jun 20, 2024, 05:06 | Blog
Pedro C Barata: Check out the wonderful editorial led by Jason Brown
Jason Brown, GU Oncologist at University Hospitals, shared a post by Pedro C Barata, GU Med Oncologist…
Jun 15, 2024, 07:36 | Blog
Tom Powles and Giorgio Bogani Discuss the Recently Published Study on Advanced or Recurrent Endometrical Cancer
The European Society for Medical Oncology (ESMO) posted on LinkedIn: “Latest podcast Annals of Oncology Editor-in-Chief…
Jun 6, 2024, 10:02 | Societies
Tom Powles: Great investigator-initiated study from LACOG and Fernando Maluf
Tom Powles, Director of Barts Cancer Center, shared a post on X: "40% response rate…
Jun 5, 2024, 12:44 | Blog
Tom Powles: Perhaps the most important long-term bladder cancer data at ASCO24
Tom Powles, Director of Barts Cancer Center, shared on X/Twitter: ''Perhaps the most important long-term…
Jun 1, 2024, 12:50 | Blog
Lennard YW Lee: We are now one of the leading cancer research infrastructure for personalised cancer vaccine trials
Lennard YW Lee, Associate Professor at the University of Oxford, shared on LinkedIn: "Feeling proud…
Jun 1, 2024, 10:00 | Insight
Tom Powles: TROPICS-4 in heavily pretreated bladder cancer missed OS
Tom Powles, Director of Barts Cancer Center, shared on X: “TROPICS-4 (sacituzumab, govitecan versus chemo) in…
May 28, 2024, 14:33 | Societies
Tom Powles: Final results for axitinib/avelumab in 1st line RCC at ASCO24
Tom Powles, Director of Barts Cancer Center, shared on X: "Final results for axitinib/avelumab in 1st…
May 28, 2024, 07:49 | Insight
Tom Powles: Renal cancer highlights at ASCO24 - KIM1 biomarker data stands out
Toni Choueiri shared a post by Tom Powles, Director of Barts Cancer Center, on X and…
May 27, 2024, 05:34 | Opinion
Tom Powles: The ASCO 24 highlight In My Opinion
Tom Powles, Director of Barts Cancer Center, shared on X: “The ASCO 24 highlight IMO. Currently…
May 26, 2024, 11:35 | Insight
Bladder cancer highlights for ASCO24 by Tom Powles
Tom Powles, Director of Barts Cancer Center, shared on X/Twitter: "Bladder cancer highlights for ASCO24. Practice…
May 26, 2024, 11:15 | Insight
Tom Powles: 3 renal cancer biomarker orals at ASCO24
Tom Powles, Director of Barts Cancer Center, shared on X/Twitter: "3 renal cancer biomarker orals at…
May 24, 2024, 00:08 | Blog
Tom Powles: Mixing papillary and other ‘non-clear cell’ renal cancers guidlines has hampered new treatments
Tom Powles, Director of Barts Cancer Center, shared on X/Twitter: "The ESMO guidlines make a clear…
May 23, 2024, 13:33 | Insight
Tom Powles: Debate about activity of neoadjuvant vs adjuvant vs both is ongoing
Tom Powles, Director of Barts Cancer Center, shared a post on X: "Neoadjuvant chemo/nivolumab with…
May 23, 2024, 13:04 | Blog
Tom Powles on the NADINA trial
Tom Powles, Director of Barts Cancer Center, shared a post on X: "The NADINA trial…
May 23, 2024, 07:58 | Insight
Tom Powles on new ESMO guidelines for renal cancer
Tom Powles, Director of Barts Cancer Center, shared on X: "New ESMO guidelines in advanced papillary…
May 18, 2024, 11:30 | Insight
Tom Powles: Annual meeting of the CARE 1 metastatic 1st line RCC study
Tom Powles, Director of Barts Cancer Center, shared a post on X: “Annual meeting of…
May 12, 2024, 14:34 | Societies
Tom Powles talks to Amanda Psyrri about immune cell-related biomarkers in HNSCC - ESMO
ESMO - European Society for Medical Oncology shared on LinkedIn: “Latest podcast Annals of Oncology…
May 12, 2024, 13:37 | Blog
Two Onc Docs: Tom Powles and Brian Rini discuss metastatic RCC
Two Onc Docs shared a post on X: "We are back this week with Tom Powles…
May 7, 2024, 10:25 | Career
Tom Powles has been named in TIME100 Health - Barts and The London School of Medicine and Dentistry
Toni Choueiri shared a post by Barts and The London School of Medicine and Dentistry…
Apr 20, 2024, 20:30 | Insight
Tom Powles: Adjuvant pembrolizumab in clear cell renal cancer for the 1st time (KN564)
Tom Powles, Director of Barts Cancer Center, recently shared on X: "Adjuvant pembrolizumab shows a…
Apr 20, 2024, 06:03 | Insight
Toni Choueiri: The long-awaited OS results from KEYNOTE-564 are out at the New England Journal of Medicine!
Toni Choueiri shared on X/Twitter: "The long-awaited OS results from KEYNOTE-564 are out at the New…
Apr 16, 2024, 01:39 | Drugs
Tom Powles reflects on conducting less successful trials in Urothelial Carcinoma
Tom Powles, Director of Barts Cancer Center, recently shared on X: "We have not had…
Apr 11, 2024, 08:13 | Drugs
Tom Powles: Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma
Tom Powles, Director of Barts Cancer Center, recently shared on X: “Trial in progress: The…
Apr 8, 2024, 15:41 | Drugs
Tom Powles: This seems an ambitious accelerated approval in UC
Tom Powles, Director of Barts Cancer Center, recently shared on X: "TDXD received FDA accelerated…
Apr 1, 2024, 19:03 | Blog
Top Influencers in GU Ocology by LARVOL
LARVOL shared on their X/Twitter page: "Delving into GU Oncology, we’re thrilled to spotlight the…
Apr 1, 2024, 15:31 | Blog
Tom Powles: Easter paper of the month with Matt Galsky
Tom Powles, Director of Barts Cancer Center, shared a post on X: "Easter paper of…
Mar 17, 2024, 19:51 | Insight
Tom Powles: New ESMO's guidlines for advanced bladder cancer Annals of Oncology - Enforumab Vedotin and pembrolizumab is the new standard of care
Tom Powles, Director of Barts Cancer Center, shared a post on X: "New ESMO's guidelines for…
Mar 15, 2024, 15:26 | Insight
Enfortumab+pembrolizumab combination as the 1st line treatment of choice for advanced urothelial cancer - summary by Piotr J. Wysocki
Piotr J. Wysocki, Professor of Medicine, Head of Department of Oncology at Jagiellonian University Hospital,…
Feb 5, 2024, 15:59 | Blog
Tom Powles: Summary of clinical trials in advanced non-clear cell RCC GU24
Tom Powles, Director of Barts Cancer Centre, shared a post on X/Twitter: “Summary of clinical…
Feb 1, 2024, 17:14 | Insight
Sumanta K. Pal: She has developed what I think should be called the 'Bergerot QOL Index ' for kidney cancer
Sumanta K. Pal, Professor and Vice Chair of Academic Affairs at City of Hope, shared…
Dec 23, 2023, 03:46 | Blog
Barts Health NHS Trust: Tom Powles features in Nature’s 10
Barts Health NHS Trust shared on LinkedIn: “A Barts Health doctor whose research has helped…
Dec 19, 2023, 09:13 | Blog
Yüksel Ürün: Congratulations to Tom Powles for being recognized as one of the top influencers in science for the year 2023 by Nature!
Yüksel Ürün, Professor at the Department of Medical Oncology, Ankara University School of Medicine, recently…
Dec 19, 2023, 09:10 | Insight
Tom Powles: EV/pembro will transform the lives of many patients with this difficult disease
Tom Powles, Director of Barts Cancer Centre, shared a post on X/Twitter: "A big day…
Dec 4, 2023, 15:11 | Blog
Tom Powles: This is the next chapter IMO
Tom Powles, Director of Barts Cancer Centre, shared a post on X/Twitter: "Treatment for muscle…
Nov 9, 2023, 18:28 | Blog
Chandler Park: Fun GU oncology weekend
Chandler Park, Voting member of the American Society of Clinical Oncology (ASCO) State Council, recently…
Nov 1, 2023, 18:54 | Societies
20 Posts Not To Miss From ESMO 2023 Congress
The Annual Congress of the European Society For Medical Oncology (ESMO) took place from October…
Oct 26, 2023, 16:27 | Blog
Benjamin Auberger: This major study naturally raises several questions
Quoting Benjamin Auberger, Oncologist at CHRU Brest, on LinkedIn: "A wow presidential session with a…
Oct 25, 2023, 17:27 | Insight
Tom Powles: TAR-210 releases Erdafitinib slowly into the bladder by a novel release system
Tom Powles, Director of Barts Cancer Centre, shared on Twitter: ''Something NEW. TAR-210 releases Erdafitinib…
Oct 23, 2023, 15:26 | Insight
Tom Powles: Enfortumab vedotin and Pembrolizumab improving PFS and OS by 55% and 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%)
Tom Powles, Director of Barts Cancer Centre, shared on Twitter: "Enfortumab vedotin and Pembrolizumab improving…
Oct 21, 2023, 14:04 | Drugs
Tom Powles: Renal cancer highlights ESMO23
Tom Powles Director of Barts Cancer Centre, shared a post on LinkedIn, saying: "Renal cancer…
Oct 14, 2023, 16:32 | Insight
Daniel Chen: After a decade of immense progress for patients with cancer immunotherapy we are excited to publish a 10-year update, reflecting the complexity in the TME.
Daniel Chen, Founder of Engenuity Life Sciences, shared on LinkedIn: "We wrote the Cancer Immunity Cycle…
Oct 12, 2023, 18:13 | Blog
María Natalia Gandur Quiroga: Fantastic review! A pleasure to read: Understanding the Cancer-Immunity Cycle.
Quoting María Natalia Gandur Quiroga on X/Twitter: "Fantastic review! A pleasure to read: Understanding the Cancer-Immunity…
Oct 6, 2023, 15:32 | Blog
Paolo Tarantino: Bright days ahead for ESMO journals!
Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared on X/Twitter: “Congrats to the…
All: 82 Posts: 1 - 100
Special Coverage